NONE, BUT I SHOULD GET SOME
|
|
- Vincent Murphy
- 5 years ago
- Views:
Transcription
1 Ma#hew West, MD Assistant Professor Department of Neurology University of Colorado NONE, BUT I SHOULD GET SOME Discuss the effect of Parkinson s Disease on mulmple organ systems Review medicamon management for symptoms in the post- operamve phase Review Parkinson s Disease medicamons, specifically their importance in the post- operamve course
2 The Shaking Man Terry Allen, year old man diagnosed with Parkinson s disease (PD) 12 years ago presents awer mechanical fall, resulmng in a distal femur fracture requiring internal fixamon surgery. Current PD medicamon regimen is: 1. Carbidopa/levodopa 25mg/100mg 5 Mmes per day 2. Entacapone 200 mg 5 Mmes per day 3. Pramipexole 1 mg 3 Mmes per day 4. Amantadine 100 mg oral twice a day WHY SHOULD WE CARE? Increased risk of nosocomial morbidity Post- operamve stays are longer than non- PD 18 days versus 14.5 days (Mueller, 2009) 11.4 days versus 8.8 days (Pepper, 1999) Overall duramon of inpament treatment significantly longer 21.4 days versus 18.2 days (Mueller, 2009) Trend towards higher inpament mortality 7.3% versus 3.8% (Pepper, 1999) Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511 Pepper, et al. J Am Geriatric Soc. 1999;47(8):967
3 Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511
4 Increased risk of post- operamve falls LimitaMons in rehabilitamon Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511 RECOMMENDATIONS Early and aggressive PT/OT Fall precaumons Early reinimamon of parkinson s medicamons
5 Can have obstrucmve or restricmve pa#ern on PFTs Increased airway resistance and decrease lung elasmc recoil lead to OBSTRUCTIVE pa#ern Rigidity of chest wall and upper airway muscles can lead to RESTRICTIVE pa#ern Pneumonia remains leading cause of mortality among PD paments Increase aspira&on risk in perioperamve period OR 3.825, p<0.001 (Pepper, 1999) Shill et al, Clin Neurosci 1998;5(2): Pepper, et al. J Am Geriatric Soc. 1999;47(8):967 RECOMMENDATIONS AspiraMon PrecauMons Swallow evaluamon early in course Inspiratory Spirometer (IS) Pulmonary Toilet Early mobilizamon Early reinimamon of parkinson s medicamons SecreMons SucMoning Glycopyrrolate 1 mg PO TID (Arbouw, Neurology 2010) Arbouw, et al. Neurology 2010;74(15):1203-7
6 Dysphagia is common in PD 50-80% on barium swallow examinamons (Castell, 2001) Secondary to abnormality of muscles in mouth, pharynx, and esophagus Increase risk of aspiramon and malnutrimon GI DysmoMlity Due to Lewy Body deposimon in Myenteric Plexus ConsMpaMon Gastroparesis Ileus Castell, et al. Neurogastroenterol Motil 2001;13(4): RECOMMENDATIONS Swallow evaluamon! Consider pre- operamve swallow evaluamon AspiraMon precaumons Monitor nutrimon closely Aggressive bowel regimen (smmulant and sowener) MobilizaMon Early reinimamon of parkinson s medicamons Avoid anm- cholinergics if possible GASTROPARESIS: Erythromycin NOT Metoclopramide
7 OrthostaMc hypotension Post- prandial hypotension Impaired heart rate (HR) variability Risk of arrhythmias with pro- dopaminergic medicamons Katus, et al. American Journal Medicine 2014;127: RECOMMENDATIONS Fall precaumons Check orthostamcs as necessary Change of posimon slowly CauMon with beta- blockers and other nodal medicamons If have orthosta&c hypotension Adequate hydramon Head- of- bed when sleeping degrees Thigh high compression stockings If severe orthostasis!abdominal binder MedicaMon opmons FludrocorMsone mg oral daily Midodrine 10 mg 3 Mmes per day during daymme
8 About one- third PD paments have demenma AddiMonal one- quarter to one- third have mild cognimve impairment (MCI) High risk of post- operamve delirium OR 2.6 versus controls (Pepper, 1999) Aarsland D, et al. Mov Disord. 2005;20(10):1255 Pepper, et al. J Am Geriatric Soc. 1999;47(8):967 RECOMMENDATIONS Delirium precaucons " Sleep/wake cycle " Hydra&on/nutri&on MedicaCons (for PD) AnMcholinergics>>Amantadine/Dopamine Agonists>>Levodopa/MAOI- B worsen delirium If need pharmacologic restraint AVOID typical anmpsychomcs (e.g., Haldol) CauMon with atypical anm- psychomcs QueCapine and Clozapine have low dopamine- blockade and are owen used
9 Undergoes successful surgery Complaining of pain in post- operamve period that is appropriately addressed Develops nausea/vomimng, cross- cover physician writes for an anm- ememc On your next examinamon, you note worsening rigidity and tremor Why? What medicacon may have been given? An#- eme#cs with dopamine (D2) blockade Metoclopramide Prochlorperazine Promethazine USE INSTEAD: Ondansetron An#- psycho#cs with high D2 blockade Typical antipsychotics Most atypical antipsychotics USE INSTEAD: Quetiapine Clozapine If on MAO- B inhibitor (selegiline, rasagiline) Cau&on with Meperidine Tramadol Methadone Dextromethorphan New SSRI, SNRI, and TCAs
10 Over the next 3 days, the pament declines clinically: Consciousness level worsens Unable to follow commands Becomes febrile to 40.2 Fluctuating heart rate Tone increased axially and in all four limbs Develops leukocytosis and elevated CK (9,000) What happened and what should be done? Similar to NeurolepMc Malignant Syndrome (NMS) Occurs about 3-4 days awer cessamon/decrease of dopaminergic medicamons Signs/symptoms High fever Muscle rigidity Autonomic instability Altered mental status (reduced consciousness) Complications Acute kidney injury Rhabdomyolysis Disseminated intravascular coagulamon Pro- Dopaminergic Carbidopa/Levodopa (Sinemet ) Dopamine Agonists Pramipexole (Mirapex ) Ropinirole (Requip ) Rotigotine (Neupro patch ) Amantadine MAO- B Inhibitors Selegiline (Eldepryl, Zelapar ) Rasagiline (Azilect ) AnC- cholinergics Trihexyphenidyl (Artane ) COMT inhibitor Entacapone (Comtan ) Tolcapone (Tasmar )
11 Start pacent s PD regimen ASAP! As close to home regimen as possible Pay azencon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night
12 Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Carbidopa/Levodopa Similar efficacy to convenconal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Effects Levodopa absorpcon Consider bolused tube feeds or starcng at night In post- operamve seong, Parkinson s Disease can have impact on mulmple organ systems Important to avoid medicamons that may worsen their disease Start pament on home parkinson s regimen as soon as possible Low threshold to consult Neurology colleagues!
13
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationFaculty Information 2/15/2013
Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey tjreilly@pharmacy.rutgers.edu Faculty Information Presenter:
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationGuidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationMedicines Management and the Unwell Parkinson s Patient
Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationThe Fresco Institute for Parkinson's and Movement Disorders
The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More information10/4/2016. Disclosures. Motor symptoms are Just the tip of the iceberg. Parkinson s Disease for the Primary Care Clinician
Disclosures Parkinson s Disease for the Primary Care Clinician Maya Katz, M.D. Assistant Professor of Neurology Movement Disorder and Neuromodulation Center UCSF Medical Center Consulting services for
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationParkinson s Disease and Treatment Options for the Younger Adult
Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand
More informationParkinson s Disease and Treatment Options for the Younger Adult
The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationPL CE LIVE July 2015 Forum
July 2015 PL CE LIVE Rachel Maynard, PharmD Associate Editor Pharmacist s Letter/Pharmacy Technician s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation
More informationParkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco
Parkinson s Disease Graham A. Glass, MD Assistant Professor of Neurology University of California San Francisco San Francisco VA Medical Center Parkinson s Disease Research, Education and Clinical Center
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationDisclosures. Objectives. What s Shaking? Tremors and Movement Disorders
Disclosures What s Shaking? Tremors and Movement Disorders Jill L. Ostrem, MD Associate Professor of Neurology Surgical Movement Disorders Center Consultant and speaker: Allergan Inc., Medtronic Inc.,
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationTremor, Rigidity, Tics and Dystonia: The 4 Most Common Movement Disorders
Tremor, Rigidity, Tics and Dystonia: The 4 Most Common Movement Disorders VIGNETTE 1: HAND SHAKING 62 YOF tremor of both hands for 6 years FHx: Shaking in mother & maternal cousin PMH: Depression, HTN,
More informationAdvances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL
Advances in Parkinson s Disease Treatment Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL Uitti.ryan@mayo.edu Ryan J. Uitti, MD Disclosure receives research support from NIH/NINDS,
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationParkinson s Pharmacology
PHPP 517 (IT-III) Fall 2011 JACOBS Wed 10/12 8:00 8:50 AM 1 Learning objectives 1. Describe the direct and indirect pathways of the extrapyramidal system and its modulation by ACh and DA. 2. Contrast the
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationThe Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates
The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates Editor: Marsha K. Millonig, MBA, RPh President/CEO Catalyst Enterprises,
More informationNMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM
Page 1 of 5 Patient Name: Date of Birth: MRN: Encounter #: NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM Thank you for taking
More informationMovement Disorders. Eric Kraus, MD! Neurology!
Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationHuntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC
Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC Huntington s Disease Typically adult-onset, autosomal dominant disorder
More informationGuideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017
Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017 1. INTRUCTION 1.1 Guideline for the management of Parkinson s Disease Medication in adult patients presenting to
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationSection 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST
4/27/2012 Parkinson's Disease Webinar April 27th, 2012 12:00-1:00 PM EST Presenter: Jon Collins, Manager, Programs and Events, Parkinson Society Central & Northern Ontario Section 1: What is Parkinson
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationHuntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Huntington s Disease
Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC Huntington s Disease Typically adult-onset, autosomal dominant disorder
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationManagement of Neurological Conditions at End of Life
Management of Neurological Conditions at End of Life Erwin B. Montgomery Jr. MD Professor of Neurology McMaster University, Hamilton ON Medical Director Greenville Neuromodulation Center, Greenville PA
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s
More informationCLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationDisclosures. Objectives. What s Shaking? Tremors and Movement Disorders
Disclosures What s Shaking? Tremors and Movement Disorders Jill L. Ostrem, MD Associate Professor of Neurology Surgical Movement Disorders Center Consultant and speaker: Allergan Inc., Medtronic Inc.,
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationManagement of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.
Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients
More informationASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease
ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease Parkinson s Disease Cardinal Signs: Resting tremor Rigidity Bradykinesia Postural instability Other Symptoms Dystonia Dysphagia Autonomic
More informationChristopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine
Christopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine 1. Medication working well but do you still need it? 2. Medication working well but do you really
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Parkinson s Choices Playing an Active Role in Your Treatment Plan Wednesday, August 17, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More information